Date: 2014-02-20
Type of information: Licensing agreement
Compound: tafoxiparin
Company: Dilafor (Sweden) Lee’s Pharmaceutical Holdings (China)
Therapeutic area: Women health
Type agreement: licensing
Action mechanism:
Disease: obstetrics and gynecological indications
Details: * On February 20, 2014, Dilafor, part of Karolinska Development’s portfolio of companies, based in Stockholm, Sweden and Lee’s Pharmaceutical Holdings Ltd, based in Hong Kong announced that they have entered into a license agreement. According to the agreement, Dilafor grants to Lee’s Pharmaceutical the right to manufacture, develop and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau and Taiwan. Pursuant to the terms of the agreement, Dilafor and Lee’s Pharmaceutical will jointly develop tafoxiparin for obstetrical and gynecological indications. The joint clinical development program of tafoxiparin will initially be focused on reducing labor times for patients who do not start labor spontaneously and are induced into labor, an indication where both Dilafor and Lees Pharmaceutical see a major medical need for the product in terms of improving outcomes for both mother and baby. In addition to the labor induction indication, tafoxiparin is intended to be used for the treatment of labor arrest. Tafoxiparin has previously been tested in a randomized, double-blind and placebo-controlled Phase II trial conducted in Sweden which included 263 pregnant women. The study showed promising results forming the basis for the continuous clinical development.
Financial terms: Dilafor will receive an upfront payment as well as future development and sales milestones plus royalties on sales of the product which will be manufactured and sold by Lee’s Pharmaceutical in China, Hong Kong, Macau and Taiwan. Lee’s Pharmaceutical will conduct and finance Phase II and Phase III trials in China, so that the results can be used as the basis for additional development outside the countries where Lee’s Pharmaceutical has its license. Further details on the terms of the agreement are not being disclosed.
Latest news:
